Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT05518292 Recruiting - Breast Cancer Clinical Trials

Comparison of Analgesic Efficacy of Ultrasound Guided Rhomboid Intercostal Block Versus Serratus Anterior Plane Block for Mastectomy Surgery

Start date: September 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Breast surgeries are usually associated with sever postoperative pain ,good perioperative analgesic technique after breast surgery is always questionable .Thoracic epidural and paravertebral blocks became the gold standard techniques for pain relief ,however they may be associated with complications such as spinal cord injury, total spinal anesthesia ,inadvertent intravascular injection and pneumothorax . Recently , fascial plane blocks have been introduced as an alternative such as erector spinae plane block and serratus plane block Serratus plane block were introduced by Blanco et al where local anesthetic injected superficial to the muscle to provide nerve block of the lateral cutaneous branches of the intercostal nerves Rhomboid intercostal block is an interfascial plane block for chest wall analgesia, it was reported in 2016 as alternative to thoracic epidural and paravertebral blocks.

NCT ID: NCT05515289 Recruiting - Breast Cancer Clinical Trials

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Start date: December 18, 2022
Phase: Phase 1
Study type: Interventional

The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 24-30 subjects. Subjects will take the SHR6390 on Day1.

NCT ID: NCT05512468 Recruiting - Breast Cancer Clinical Trials

Application of Preoperative Axillary Lymph Node Marking With Nano-Carbon in Breast Cancer Patients Before Neoadjuvant Chemotherapy

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The primary aim of this prospective, multicentre study is to determine whether the involved node can be marked using black carbon dye and successfully identified at the time of surgery. The secondary aims are to determine the concordance between the tattooed node and sentinel node, migration of black dye into other nodes, and false-negative rate of tattooed node (in patients undergoing ALND after NACT).

NCT ID: NCT05512416 Not yet recruiting - Breast Cancer Clinical Trials

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Start date: August 2022
Phase: Phase 2
Study type: Interventional

In this single arm, open label, phase 2 trial, operable patients with stage IIB-III HR+/HER2- breast cancer will be enrolled and receive six cycles of adjuvant dalpiciclib plus letrozole. This study aims to assessed the biological effects and safety of dalpiciclib in combination with letrozole for HR+/HER2- breast cancer in the neoadjuvant setting.

NCT ID: NCT05512286 Not yet recruiting - Breast Cancer Clinical Trials

Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction

CAPPELLA
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This study is the first prospective randomized study assessing the patient-reported outcomes and safety outcomes between preoperative and postmastectomy radiotherapy in locally advanced breast cancer patients with immediate reconstruction of deep inferior epigastric perforator(DIEP) flap. Radiotherapy before mastectomy and autologous free-flap breast reconstruction can avoid adverse radiation effects on healthy donor tissues and delays to adjuvant radiotherapy. We aimed to explore the feasibility of preoperative radiotherapy followed by DIEP flap reconstruction in patients with breast cancer requiring mastectomy.

NCT ID: NCT05510037 Completed - Breast Cancer Clinical Trials

Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions

Start date: January 1, 2021
Phase:
Study type: Observational

About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.

NCT ID: NCT05509829 Recruiting - Breast Cancer Clinical Trials

EvaLuating negAtive pressUre Wound theRapy in brEast coNserving Surgery

LAUREN
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

Negative pressure wound therapy (NPWT) could improve surgical outcomes and reduce complications like SSI, wound dehiscence and seroma in closed surgical wounds. To date, NPWT was not evaluated in patients undergoing breast conserving surgery without direct reconstruction.Therefore, the aim of this trial is to evaluate the feasibility of NPWT after surgery and its effects on postoperative complications.

NCT ID: NCT05508984 Active, not recruiting - Breast Cancer Clinical Trials

Clinical Outcomes and Patient Satisfaction With Use of the Amma System

Start date: August 22, 2022
Phase:
Study type: Observational

The primary goal is to conduct a pilot evaluation of the Amma device, to determine whether it is feasible to offer as an option for patients within oncology suites within the PH&S system.

NCT ID: NCT05507879 Recruiting - Breast Carcinoma Clinical Trials

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Start date: August 18, 2022
Phase:
Study type: Observational

This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of certain cancer related therapies. Understanding these changes may allow early intervention against therapy-related cardiac toxicity and also identify novel therapeutic targets to protect patient long-term cardiac health. Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA), identify biomarkers related to cardiac toxicity, and prevent the development of therapy-induced cardiac toxicity in patients receiving chemotherapy.

NCT ID: NCT05507398 Not yet recruiting - Clinical trials for Breast Cancer Female

The Anti-tumor Effect of Metformin And Atorvastatin in Breast Cancer

Start date: October 2022
Phase: Phase 4
Study type: Interventional

This study aims at evaluating and comparing the anti-tumor effects of metformin and statins (hydroxyl-methyl-glutaryl-CoA reductase inhibitors) in patients with non-metastatic breast cancer (stage I, II, & III).